A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.
Stanford is now accepting new patients for this trial.
- drug : Fulvestrant
- drug : Trastuzumab
- drug : Neratinib
Phase: Phase 2
Ages Eligible For Study: